Risk factors and prognosis of postoperative early relapse after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a retrospective study.

IF 2.5 3区 医学 Q3 ONCOLOGY
Ze-Gang Chen, Yue-Yun Chen, Zhen Lin, Pan-Pan Lin, Qing Li, Yu-Shang Yang, Hua-Shan Shi, Zhen-Yu Ding
{"title":"Risk factors and prognosis of postoperative early relapse after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a retrospective study.","authors":"Ze-Gang Chen, Yue-Yun Chen, Zhen Lin, Pan-Pan Lin, Qing Li, Yu-Shang Yang, Hua-Shan Shi, Zhen-Yu Ding","doi":"10.1186/s12957-025-03985-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify risk factors associated with early postoperative relapse and evaluate their impact on survival outcomes after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC), thereby informing strategies to optimize postoperative clinical management.</p><p><strong>Methods: </strong>Patients with LA-ESCC who underwent neoadjuvant therapy followed by surgical resection at West China Hospital between January 2018 and December 2023 were screened and enrolled. Patients were categorized into early relapse (≤ 6 months) and late relapse (> 6 months) groups based on the interval from surgery to relapse.</p><p><strong>Results: </strong>A total of 183 LA-ESCC patients who received neoadjuvant therapy followed by surgical resection were included, with 79 experiencing early relapse and 104 experiencing late relapse. Logistic regression analysis showed that postoperative TNM stage III-IV, ypN + stage, R1 resection, lymphovascular invasion (LVI), perineural invasion (PI), and absence of postoperative adjuvant therapy were risk factors for early relapse (p < 0.05). Multivariate regression further identified R1 resection as an independent predictor (p < 0.05). Cox regression analysis demonstrated that LI was a prognostic factor for overall survival (OS) in patients with early relapse (p = 0.045). Kaplan-Meier analysis revealed significantly reduced OS (12.5 months vs. 26.9 months, HR = 2.96, p < 0.001) and survival after relapse (SAR) (5.9 months vs. 11.0 months, HR = 1.81, p < 0.001) in the early relapse group compared to the late relapse group. However, relapse patterns did not differ significantly between groups (p > 0.05).</p><p><strong>Conclusion: </strong>R1 resection is an independent risk factor for rapid postoperative relapse in LA-ESCC patients following neoadjuvant therapy. Furthermore, LVI significantly affects patients survival outcomes, and early relapse was strongly associated with reduced overall survival (OS).</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"354"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487306/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12957-025-03985-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aimed to identify risk factors associated with early postoperative relapse and evaluate their impact on survival outcomes after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC), thereby informing strategies to optimize postoperative clinical management.

Methods: Patients with LA-ESCC who underwent neoadjuvant therapy followed by surgical resection at West China Hospital between January 2018 and December 2023 were screened and enrolled. Patients were categorized into early relapse (≤ 6 months) and late relapse (> 6 months) groups based on the interval from surgery to relapse.

Results: A total of 183 LA-ESCC patients who received neoadjuvant therapy followed by surgical resection were included, with 79 experiencing early relapse and 104 experiencing late relapse. Logistic regression analysis showed that postoperative TNM stage III-IV, ypN + stage, R1 resection, lymphovascular invasion (LVI), perineural invasion (PI), and absence of postoperative adjuvant therapy were risk factors for early relapse (p < 0.05). Multivariate regression further identified R1 resection as an independent predictor (p < 0.05). Cox regression analysis demonstrated that LI was a prognostic factor for overall survival (OS) in patients with early relapse (p = 0.045). Kaplan-Meier analysis revealed significantly reduced OS (12.5 months vs. 26.9 months, HR = 2.96, p < 0.001) and survival after relapse (SAR) (5.9 months vs. 11.0 months, HR = 1.81, p < 0.001) in the early relapse group compared to the late relapse group. However, relapse patterns did not differ significantly between groups (p > 0.05).

Conclusion: R1 resection is an independent risk factor for rapid postoperative relapse in LA-ESCC patients following neoadjuvant therapy. Furthermore, LVI significantly affects patients survival outcomes, and early relapse was strongly associated with reduced overall survival (OS).

Abstract Image

Abstract Image

Abstract Image

局部晚期食管鳞状细胞癌新辅助治疗后早期复发的危险因素及预后回顾性研究
背景:本研究旨在确定与局部晚期食管鳞状细胞癌(LA-ESCC)术后早期复发相关的危险因素,并评估其对新辅助治疗后生存结局的影响,从而为优化术后临床管理提供策略。方法:筛选2018年1月至2023年12月在华西医院接受新辅助治疗并手术切除的LA-ESCC患者。根据手术至复发的时间间隔将患者分为早期复发组(≤6个月)和晚期复发组(> 6个月)。结果:共纳入183例接受新辅助治疗后手术切除的LA-ESCC患者,其中早期复发79例,晚期复发104例。Logistic回归分析显示,术后TNM III-IV期、ypN +期、R1切除、淋巴血管侵犯(LVI)、神经周侵犯(PI)、术后未接受辅助治疗是早期复发的危险因素(p 0.05)。结论:R1切除是LA-ESCC患者新辅助治疗后快速复发的独立危险因素。此外,LVI显著影响患者的生存结果,早期复发与总生存期(OS)降低密切相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
15.60%
发文量
362
审稿时长
3 months
期刊介绍: World Journal of Surgical Oncology publishes articles related to surgical oncology and its allied subjects, such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology. Emphasis is placed on original research articles. The journal also publishes significant clinical case reports, as well as balanced and timely reviews on selected topics. Oncology is a multidisciplinary super-speciality of which surgical oncology forms an integral component, especially with solid tumors. Surgical oncologists around the world are involved in research extending from detecting the mechanisms underlying the causation of cancer, to its treatment and prevention. The role of a surgical oncologist extends across the whole continuum of care. With continued developments in diagnosis and treatment, the role of a surgical oncologist is ever-changing. Hence, World Journal of Surgical Oncology aims to keep readers abreast with latest developments that will ultimately influence the work of surgical oncologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信